Akosua Adom Agyeman

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 391 citations · Full text

Long Covid, Treatment And Prevention, Covid-19 Pandemic +9

Irrational Use of Medicines—A Summary of Key Concepts

Richard Ofori‐Asenso, Akosua Adom Agyeman · Pharmacy · 2016 · 275 citations · Full text

Tuberculosis—an overview

Akosua Adom Agyeman, Richard Ofori‐Asenso · Journal of Public Health and Emergency · 2017 · 38 citations · Full text

Treatment Guidelines, Pulmonary Tuberculosis, Global Health +10

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Joseph F. Standing, Laura Buggiotti, José Afonso Guerra‐Assunção et al. · Nature Communications · 2024 · 38 citations · Full text

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19

David M. Lowe, Li‐An K. Brown, Kashfia Chowdhury et al. · PLoS Medicine · 2022 · 31 citations · Full text